Track topics on Twitter Track topics that are important to you
AstraZeneca is hoping new data showing its Bydureon diabetes drug cuts overall death risk could stave off competition from Novo Nordisk's potential next generation GLP-1 drug. Bydureon (exenatide), a weekly type 2 diabetes GLP-1 class injection, i...
Original Article: AZ talks up Bydureon data, GLP-1 and glucagon comboNEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...